×

Prostate Cancer Research: From Risk to Robotic Prostate Surgery

American Urological Association Annual Meeting (AUA)
RoboticOncology

San Diego, CA, May 3, 2013 (GLOBE NEWSWIRE) -- World-renowned robotic prostate surgeon and research authority, Dr. David Samadi, will be featured at the annual meeting of the American Urological Association (AUA) this weekend in San Diego. As lead researcher on distinct prostate cancer studies, Dr. Samadi and his research team will present findings on topics ranging from prostate cancer risk to robot-assisted laparoscopic prostatectomy (RALP) treatment outcomes.

Lead researcher and Mount Sinai robotic prostate surgeon, David B. Samadi, MD, to present at American Urological Association Annual Meeting (AUA) in San Diego, California, that begins May 4, 2013


http://www.globenewswire.com/newsroom/prs/?pkgid=17463

As Chief of Robotics and Minimally Invasive Surgery and Vice Chairman of the Department of Urology at The Mount Sinai Medical Center, Dr. Samadi is a prostate cancer treatment expert, leading robotic prostate surgeon, and global educator of his highly regarded Samadi Modified Advanced Robotic Technique (SMART) custom prostate removal surgery.

Four of Dr. Samadi's top research initiatives will be presented at this year's AUA meeting:

Effects of Metabolic Syndrome on Pathologic Features and Surgical Outcomes after Robot-Assisted Laparoscopic Prostatectomy

In a nine-year review of more than 2,600 of RALP procedures, patients who met the criteria for metabolic syndrome were found to have larger prostates, higher pathologic Gleason scores, higher tumor volume, and increased surgical complexity. Metabolic syndrome is defined as obesity plus related cardiovascular disease risk factors. Encouraging results demonstrated that patients with metabolic syndrome had surgical outcomes similarly favorable to non-obese patients.

Risk-adjusted Actual Hospital Costs of the Primary Treatment of Prostate Cancer: A Contemporary Experience of Multidisciplinary Cancer Center

A four-year query of patients undergoing prostate cancer treatment compared actual hospital costs for RALP, brachytherapy, intensity modulated radiotherapy (IMRT), and various combination therapies. While the treatments provide comparable oncologic outcomes and health related quality of life, RALP consistently proves to be among the least expensive modalities for treating low, intermediate, and high risk patients when performed in a high volume setting.

Decisional Regret after Robotic-Assisted Laparoscopic Prostatectomy: The Role of Race

At nearly a year and a half post-RALP, the majority of patients did not regret their decision to have robotic prostate surgery. Decisional regret was more common among black men (20%) than Caucasian men (11%). Results indicate that race may play a significant role in decisional regret after surgery, with unique considerations for patient age, biomechanical recurrence, and post-operative continence. Expanding on this must be done with great cultural sensitivity.

Are All D'Amico Intermediate Risk Prostate Cancer Patients Equal? Heterogeneity of Intermediate Risk Patients by Gleason Score

Abstract and Conclusions:

Using D'Amico, a common risk stratification schema, and biopsy Gleason scores, a cohort of prostate cancer patients were categorized by low risk, intermediate risk, and high risk. Intermediate risk patients demonstrated significant heterogeneity in both pathologic outcomes and biomechanical disease-free survival. Factors for worsened or locally advanced disease were explored.

Follow more breaking news and prostate cancer research by Dr. Samadi at http://www.roboticoncology.com.

Related Sites:

http://www.roboticoncology.com/

http://www.smart-surgery.com/

A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=18520

CONTACT: David B. Samadi, MD Ann Angcaya 1-855-DRSAMADI 1-212-241-8779 http://www.roboticoncology.com/contact/ http://www.smart-surgery.com/contact/

Source: RoboticOncology